The Swedish company has won the backing of the investment company Blue, which has placed an additional SEK 10 million investment (together with investments from the executives at the company) in the company following an earlier round of SEK93 million announced in April this year.
The capital intake from Blue will enable Coala Life to further accelerate its current commercialization activities around its digital heart monitor and spur its launch into the United States.
“A pioneer in digital heart diagnosis and individual focused medical innovations, Coala Life has recently secured 510(k) approval from the U.S. FDA, which opens the door to the huge American marketplace for company’s unique heart monitor system that helps predict and prevent heart disease,” said Anders Jacobson, co-founder and CEO of Blue.
Puting people in control of their own heart health
The Coala Life medical system allows individuals to record and analyse their heart beat and ECG in just sixty seconds using smart, cloud-based algorithms that analyze and monitor Atrial Fibrillation (based on P-wave detection and RR variability) and eight other arrhythmia’s as well as detect murmurs. Ideal for smart remote assessments and telemedicine, the results are presented in the Coala App and the Coala Care cloud based system within seconds.
“By putting people in control of their own heart health, the Coala Life system typifies the game-changing sustainable tech innovations for people’s health that Blue focuses its investment strategies on and wants to make happen,” said Anders Jacobson.
Photo Coala Heart Monitor